Stay updated on IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.

Latest updates to the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page
- Check5 days agoChange DetectedNew revision label v3.5.5 was added to the record history, replacing the previous v3.5.4. This indicates an update to the page's versioning information.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe revision label updated from v3.5.3 to v3.5.4, indicating a newer build of the page. This change is a metadata/version update and does not affect the study information or user-facing content.SummaryDifference0.1%

- Check48 days agoChange DetectedThis updates the page’s displayed platform/interface revision from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check55 days agoChange DetectedThe history now includes Revision: v3.5.2 and removes Revision: v3.5.0.SummaryDifference0.1%

- Check84 days agoChange DetectedSystem revision history updated to add v3.5.0 and remove v3.4.3.SummaryDifference0.1%

- Check98 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed from the history.SummaryDifference0.1%

Stay in the know with updates to IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.